

UNITED STAT STATE DEPARTMENT OF COMMERCE Patent and Trademark Office


Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

FILING DATE PLACY MANTE STORM YORK SETIAL NUMBER 07/461,262 01/05/90 BARBERICH SPC8905 ELECTION AT SCHENKMAN, L HAMILTON, BROOK, SMITH & REYNOLDS TWO MILTIA DRIVE TOWT PAPER NUMBER LEXINGTON, MA 02173-4799 125 Special States 08/20/90 this is a communication from the examiner in charge of your application. COMMISSIONER OF PATENTS AND TRADEMARKS This application has been examined Responsive to communication filed on_ This action is made final. A shortened statutory period for response to this action is set to expire _______ days from the date of this letter. month(s), Failure to respond within the period for response will cause the application to become abandoned. 35 U.S.C. 133 Part I THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION: Notice of References Cited by Examiner, PTO-892. 2. Notice re Patent Drawing, PTO-948. 3. Notice of Art Cited by Applicant, PTO-1449. 4. Notice of Informal Patent Application, Form PTO-152 5. Information on How to Effect Drawing Changes, PTO-1474. Part II SUMMARY OF ACTION are pending in the application. 1. Claims Of the above, claims are withdrawn from consideration. 2. Claims have been cancelled. are allowed. 5. Claims are objected to. are subject to restriction or election requirement. 7. This application has been filed with informal drawings under 37 C.F.R. 1.85 which are acceptable for examination purposes. 8. Formal drawings are required in response to this Office action. 9. The corrected or substitute drawings have been received on . Under 37 C.F.R. 1.84 these drawings are acceptable; not acceptable (see explanation or Notice re Patent Drawing, PTO-948). 10. The proposed additional or substitute sheet(s) of drawings, filed on ____ ____ has (have) been approved by the examiner; disapproved by the examiner (see explanation). 11. The proposed drawing correction, filed_ _, has been 🔲 approved; 🗖 disapproved (see explanation). 12. 🔲 Acknowledgement is made of the claim for priority under U.S.C. 119. The certified copy has 🗎 been received 📋 not been received ☐ been filed in parent application, serial no. _ ___; filed on _ 13. Since this application apppears to be in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213. 14. Other

EXAMINER'S ACTION

PTOL-326 (Rev.9-89)





Serial No. 07/461,262

Art Unit 125

The following is a quotation of 35 U.S.C. § 103 which forms the basis for all obviousness rejections set forth in this Office action:

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

Claims 1-12 are rejected under 35 U.S.C. § 103 as being unpatentable over the Chemical Abstracts reference which teaches salbutamol (albuterol) used to treat asthma and compositions containing same. The determination of a particular isomer to employ would be a matter of obvious, alternatives to one skilled in the art. Allegations of reduced side effects are not persuasive since this has not been clinically established. Further, difference is activity between isomers is not unexpected; see In re Adamson et al, 125 USPQ 233.

Claims 9-12 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The claims lack proportions of

Art Unit 125

ingredients. The amount of the R isomer appears to relate to the entire composition rather than total albuterol.

TEUNARD SCHENKMAN EXAMINER ART UNIT 125

Schenkman:st August 10, 1990